Moderna, Inc.
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Recognized from beginning deferred revenue by Year
Recognized from beginning deferred revenue — Grants (legacy) ($M) ($M)
Moderna Recognized from beginning deferred revenue: $7M in FY2024, up 250.0% from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-21) ↗
Reported in Form 10-Q / 10-K Contract Liabilities.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Recognized from beginning deferred revenue — Grants (legacy) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 7 | +250.0% | Form 10-K (filed 2025-02-21) ↗ |
| FY2023 | Dec 31, 2023 | 2 | – | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 0 | -100.0% | Form 10-K (filed 2023-02-24) ↗ |
| FY2021 | Dec 31, 2021 | 12 | +76.5% | Form 10-K (filed 2022-02-25) ↗ |
| FY2020 | Dec 31, 2020 | 6.80 | – | Form 10-K (filed 2021-02-26) ↗ |
Cite this data
StockData. (2026). Moderna Recognized from beginning deferred revenue ($M), annual FY2020–FY2024 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/def-rev-rec-grant-leg
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.